6-K
Satellos Bioscience Inc. (MSLE)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number: 001-43107
SATELLOS BIOSCIENCE INC. (Translation of registrant's name into English)
Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800Toronto, Ontario, ON M5J 2J3 (Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [ X ]
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
| Exhibit | Description |
|---|---|
| 99.1 | Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SATELLOS BIOSCIENCE INC. | |
|---|---|
| (Registrant) | |
| Date: April 9, 2026 | /s/ Elizabeth Williams, CPA, CA |
| Elizabeth Williams, CPA, CA | |
| Chief Financial Officer |
EdgarFiling EXHIBIT 99.1
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)(“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.
Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.
2026 Bloom Burton & Co. Healthcare Investor Conference Format: Presentation and webcast Presenter: Frank Gleeson, President and CEO Date: Tuesday, April 21 Time: 11:30 a.m. ET Location: Metro Toronto Convention Centre
The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website, and a replay will be available following the presentation.
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to address deficits in muscle repair and regeneration. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental stem cell driven process that is disrupted in DMD and other degenerative conditions. By addressing the loss in a dystrophin-independent manner, SAT-3247 may re-establish the biochemical signals needed to support muscle regeneration, with potential broad applicability as either a stand-alone or adjunctive therapy. Satellos has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.
CONTACTS
Investors: Dan Ferry, LifeSci Advisors, [email protected] Media: Emily Williams, Senior Director of Communications, [email protected]